



Employee Stock Issue

Charenton-le-Pont France (November 27, 2012 - 6:00 p.m.) - At the Extraordinary Shareholders' Meeting of May 11, 2012, Essilor International's Board of Directors was given a 21-month authorization to issue shares to members of Essilor employee stock ownership plans (9th resolution). The maximum number of common shares authorized for issuance was set at 3,196,079, representing no more than 1.5% of capital stock.

At its meeting on November 27, 2012, the Board of Directors decided to use this authorization to issue up to 450,000 common shares for subscription by members of the Essilor / BBGR / Novisia / BNL Eurolens / Delamare Sovra and OMI employee stock ownership plans.

The new shares will carry rights as from January 1st, 2012. They will be offered at a price of €57.08 per share, corresponding to the average of the opening prices quoted over the last twenty trading days preceding the Board's November 27, 2012 decision to issue the shares, less a 20% discount.

Employees may purchase the shares through two funds. These funds have been given a specific value since January 1st, 2012, the start date of the subscription period. The closing date of the subscription period is December 17, 2012. The actual number of shares issued will be announced on December 21, 2012 and the Company will then apply for the new shares (par value: €0.18) to be listed on Nyse Euronext™.

The Company's capital stock amounts to €38,352,952.08, represented by 213,071,956 shares.

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around €150 million to research and development every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog™ and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of €4.2 billion in 2011 and employs around 48,700 people in some 100 countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16